Below are some of the key findings from this glioma therapeutics market analysis report
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Get a FREE sample now!
Global glioma therapeutics industry overview
The expected approval of late-stage pipeline molecules is driving the global glioma therapeutics market. The market is currently experiencing an acute lack of approved therapies due to non-availability of any promising treatment for glioma with minimal side effects. These late-stage pipeline molecules can tap into this unmet demand from the glioma patent pool and once these molecules are launched, the global glioma therapeutics market will witness strong growth.
Also, strategic alliances will positively impact the global glioma therapeutics market as it helps companies to develop and introduce the glioma drugs into the market at a rapid pace. The excepted approval of late-stage pipeline molecules coupled with strategic alliances is driving the glioma therapeutics market growth at a CAGR of more than 9% during the forecast period.
Top glioma therapeutics companies covered in this market research report
The global glioma therapeutics market is highly fragmented. The market is in the growth phase and the competition is expected to become more intense by the end of the forecast period. To help clients improve their revenue shares in the market, this research report provides an analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this glioma therapeutics market analysis report suggests strategies companies can follow and recommends key areas they should focus on, to make the most of upcoming growth opportunities.
The report offers a detailed analysis of several leading glioma therapeutics companies including:
- F. Hoffmann-La Roche
- Merck Sharp & Dohme
- Mylan
- NextSource Biotechnology
- Novartis
Glioma therapeutics market segmentation based on product
- Small molecules
- Biologics
Small molecules were the dominating product of the global glioma therapeutics market in 2018, owing to its high availability in the healthcare sector. The market share of this segment will continue to dominate the market throughout the next five years.
Glioma therapeutics market segmentation based on region
The Americas accounted for the largest glioma therapeutics market share in 2018, owing to the rising awareness about the disease and recent approvals of biosimilars in the region. The Americas will remain the market leader for the next five years.
Key highlights of the global glioma therapeutics market for the forecast years 2019-2023:
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the growth of the glioma therapeutics market during the next five years
- Precise estimation of the global glioma therapeutics market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the glioma therapeutics industry across the Americas, APAC, and EMEA
- A thorough analysis of the market’s competitive landscape and detailed information on several vendors
- Comprehensive details on factors that will challenge the growth of glioma therapeutics companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- 2.1 Preface
- 2.2 Preface
- 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Small molecules - Market size and forecast 2018-2023
- Biologics - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 12: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- F. Hoffmann-La Roche
- Merck Sharp & Dohme
- Mylan
- NextSource Biotechnology
- Novartis
PART 13: APPENDIX
- Research methodology
- List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape